At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 31–40 of 584 results.
-
This purpose of this study is to assess whether adding trastuzumab/hyaluronidase-oysk or pertuzumab/trastuzumab/hyaluronidase-zzxf to the usual chemotherapy (paclitaxel and carboplatin) shrinks tumors in patients with HER2-positive endometrial serous carcinoma or carcinosarcoma.
-
Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.
-
The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.
-
Researchers want to see how well tivozanib plus pembrolizumab works in people with kidney cancer. The people in this study had surgery for renal cell carcinoma and have a high risk of it coming back.
-
The standard treatment for poor-risk and intermediate-risk germ cell tumors (GCTs), such as testicular cancer, is chemotherapy with the drugs bleomycin, etoposide, and cisplatin (abbreviated BEP) given every three weeks. In this study, researchers want to see if giving BEP chemotherapy every two weeks is more effective for controlling tumor growth than the standard regimen in patients with metastatic intermediate-risk and poor-risk GCTs.
-
The purpose of this study is to see how well zipalertinib works to treat advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread. The cancer also has a mutation (change) in the EGFR gene. When people have an EGFR mutation, the EGFR protein on their cells can trigger cancer growth.
-
Wilms tumor the most common type of kidney cancer in children. Favorable tissue (histology) Wilms tumors (FHWT) are the most common subtype.
-
In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.
-
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).
-
V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein).